Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway

被引:43
作者
Cao, Jian [1 ]
Tsenovoy, Peter L. [2 ]
Thompson, Ellen A. [3 ]
Falck, John R. [4 ]
Touchon, Robert [3 ]
Sodhi, Komal [3 ]
Rezzani, Rita [2 ]
Shapiro, Joseph I. [3 ]
Abraham, Nader G. [2 ,3 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Marshall Univ, Joan C Edwards Sch Med, Huntington, WV 25701 USA
[4] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
Epoxyeicosatrienoic acid; Heme oxygenase-1; Myocardial infarction; Angiogenesis; Wnt1; HIGH-FAT DIET; IMPROVES INSULIN SENSITIVITY; HEME OXYGENASE-1; 11,12-EPOXYEICOSATRIENOIC ACID; CARBON-MONOXIDE; MYOCARDIAL-INFARCTION; VASCULAR DYSFUNCTION; OXIDATIVE STRESS; UP-REGULATION; STEM-CELLS;
D O I
10.1016/j.prostaglandins.2015.01.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myocardial infarction (MI) is complicated by ventricular fibrosis and associated diastolic and systolic failure. Emerging studies implicate Wnt1 signaling in the formation of new blood vessels. Epoxyeicosatrienoic acids (EETs)-mediated up-regulation of heme oxygenase-1 (HO-1) protects against the detrimental consequences of MI in several animal models, however, the mechanism(s) by which this occurs remains unclear. The aim of this study was to examine these mechanisms in the LAD ligation animal model of post infarcted heart failure. Specifically, we sought to clarify the mechanistic basis of the interactions of the Wnt1 canonical pathway, HO-1 and associated angiogenesis. Human microvascular endothelial cells (HMECs) were exposed to anoxia and treated with the EET agonist, NUDSA, in the presence and absence of tin mesoporphyrin (SnMP). Increased capillary density, and Wnt1 and HO-1 expression occurred in cells treated with NUDSA. Anoxic HMECs treated with NUDSA and Wnt1 siRNA, exhibited decreased in the expression of beta-catenin and the Wnt1 target gene, PPAR delta (p < 0.05 vs. NUDSA). Furthermore, blocking the Wnt1 antagonist, Dickkopf I, by siRNA increased beta-catenin and PPAR delta expression, and this effect was further enhanced by the concurrent administration of NUDSA. In in vivo experiments, C57B16 mice were divided into 4 groups: sham, mice with MI via LAD ligation and mice with MI treated with NUDSA, with and without SnMP. Increased fractional area change (FAC) and myocardial angiogenesis were observed in mice treated with NUDSA (p < 0.05 vs. MI). Increased expression of HO-1, Wnt1, beta-catenin, adiponectin, and phospho-endothelial nitric oxide synthetase (p-eNOS), and a decrease in the glycosylated subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, gp91(phox) expression occurred in cardiac tissue of mice treated with NUDSA (p < 0.05 vs. MI). SnMP reversed these effects. This novel study demonstrates that increasing the canonical Wnt1 signaling cascade with the subsequent increase in HO-1, adiponectin and angiogenesis ameliorates fibrosis and cardiac dysfunction in a mouse model of MI and supports the hypothesis that HO-1 is an integral component of the EETs-adiponectin axis and is central for the control of resistance to fibrosis and vascular dysfunction and in part determine how they influence the cellular/vascular homeostasis and provides insight into the mechanisms involved in vascular dysfunction as well as potential targets for the treatment of CVD. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:76 / 86
页数:11
相关论文
共 73 条
  • [1] Pharmacological and clinical aspects of heme oxygenase
    Abraham, Nader G.
    Kappas, Attallah
    [J]. PHARMACOLOGICAL REVIEWS, 2008, 60 (01) : 79 - 127
  • [2] CYP2J2 Targeting to Endothelial Cells Attenuates Adiposity and Vascular Dysfunction in Mice Fed a High-Fat Diet by Reprogramming Adipocyte Phenotype
    Abraham, Nader G.
    Sodhi, Komal
    Silvis, Anne M.
    Vanella, Luca
    Favero, Gaia
    Rezzani, Rita
    Lee, Craig
    Zeldin, Darryl C.
    Schwartzman, Michal L.
    [J]. HYPERTENSION, 2014, 64 (06) : 1352 - U413
  • [3] Heme oxygenase and the cardiovascular-renal system
    Abraham, NG
    Kappas, A
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2005, 39 (01) : 1 - 25
  • [4] THE RELATIONSHIP BETWEEN MEDIAN NERVE SOMATOSENSORY EVOKED-POTENTIAL LATENCIES AND AGE AND GROWTH-PARAMETERS IN YOUNG-CHILDREN
    BARTEL, P
    CONRADIE, J
    ROBINSON, E
    PRINSLOO, J
    BECKER, P
    [J]. ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1987, 68 (03): : 180 - 186
  • [5] Hibernating myocardium in heart failure
    Bhatia, Gurbir
    Sosin, Michael
    Leahy, John F.
    Connolly, Derek L.
    Davis, Russell C.
    Lip, Gregory Y. H.
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2005, 3 (01) : 111 - 122
  • [6] Increase in heme oxygenase-1 levels ameliorates renovascular hypertension
    Botros, FT
    Schwartzman, ML
    Stier, CT
    Goodman, AI
    Abraham, NG
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (06) : 2745 - 2755
  • [7] Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity
    Camacho, M
    Löpez-Belmonte, J
    Vila, L
    [J]. CIRCULATION RESEARCH, 1998, 83 (04) : 353 - 365
  • [8] New role for epoxyeicosatrienoic acids as anti-inflammatory mediators
    Campbell, WB
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (04) : 125 - 127
  • [9] High fat diet enhances cardiac abnormalities in SHR rats: Protective role of heme oxygenase-adiponectin axis
    Cao, Jian
    Sodhi, Komal
    Puri, Nitin
    Monu, Sumit R.
    Rezzani, Rita
    Abraham, Nader G.
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2011, 3
  • [10] Lentiviral-Human Heme Oxygenase Targeting Endothelium Improved Vascular Function in Angiotensin II Animal Model of Hypertension
    Cao, Jian
    Sodhi, Komal
    Inoue, Kazuyoshi
    Quilley, John
    Rezzani, Rita
    Rodella, Luigi
    Vanella, Luca
    Germinario, Lucrezia
    Stec, David E.
    Abraham, Nader G.
    Kappas, Attallah
    [J]. HUMAN GENE THERAPY, 2011, 22 (03) : 271 - 282